Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 2,200 shares of the stock in a transaction on Friday, December 28th. The stock was sold at an average price of $15.15, for a total value of $33,330.00. Following the completion of the sale, the chief executive officer now directly owns 743,675 shares in the company, valued at $11,266,676.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Atara Biotherapeutics Inc (NASDAQ:ATRA) opened at $20.70 on Thursday. Atara Biotherapeutics Inc has a 52 week low of $11.80 and a 52 week high of $23.00. The firm has a market capitalization of $633.33, a PE ratio of -5.97 and a beta of 1.27.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.05). sell-side analysts predict that Atara Biotherapeutics Inc will post -4 earnings per share for the current fiscal year.
A number of hedge funds have recently made changes to their positions in ATRA. Schwab Charles Investment Management Inc. boosted its stake in Atara Biotherapeutics by 16.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 92,974 shares of the biotechnology company’s stock valued at $1,302,000 after buying an additional 13,394 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Atara Biotherapeutics by 11.3% during the second quarter. Rhumbline Advisers now owns 31,373 shares of the biotechnology company’s stock valued at $439,000 after purchasing an additional 3,175 shares during the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Atara Biotherapeutics during the second quarter valued at $252,000. Bank of New York Mellon Corp lifted its holdings in shares of Atara Biotherapeutics by 4.7% during the second quarter. Bank of New York Mellon Corp now owns 125,713 shares of the biotechnology company’s stock valued at $1,760,000 after purchasing an additional 5,616 shares during the last quarter. Finally, Marshall Wace North America L.P. purchased a new stake in shares of Atara Biotherapeutics during the second quarter valued at $425,000. 85.61% of the stock is owned by institutional investors and hedge funds.
Several equities research analysts have weighed in on ATRA shares. Canaccord Genuity reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research report on Thursday, November 9th. Jefferies Group reissued a “buy” rating and issued a $30.00 price target on shares of Atara Biotherapeutics in a research note on Thursday, October 5th. Goldman Sachs Group reissued a “neutral” rating and issued a $20.00 price target on shares of Atara Biotherapeutics in a research note on Friday, October 6th. ValuEngine raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. Finally, Citigroup raised Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 price target for the company in a research note on Wednesday, January 3rd. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $26.00.
COPYRIGHT VIOLATION WARNING: “Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover Sells 2,200 Shares” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/11/isaac-e-ciechanover-sells-2200-shares-of-atara-biotherapeutics-inc-atra-stock.html.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.